Weitzel et al have already demonstrated that mutations in PALB2 and CHEK2 are associated with having two or more breast cancers, but the same study found that neither ATM nor NBN reached statistical significance for two or more breast cancers (Weitzel, 2021). Here, CHEK2 is linked to breast carcinoma.